New study aims to crack the code on cancer drug resistance
NCT ID NCT07259226
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well certain markers in tumors can predict whether a type of targeted cancer treatment called antibody-drug conjugates (ADCs) will work. About 400 adults with advanced breast, stomach, bladder, or lung cancer will provide tumor samples before and after treatment. The goal is to understand why some cancers become resistant to these drugs, which could help doctors choose better treatments in the future.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gustave Roussy Cancer Center
RECRUITINGVillejuif, 94805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can a pill combo outpace chemotherapy for aggressive breast cancer?
- Smart cancer therapy: tailoring lung cancer treatment with a simple blood test
- Blood tests could reveal hidden resistance in breast cancer
- Triple threat: three new targeted drugs join forces with immunotherapy to attack Hard-to-Treat breast cancer
- New drug sequence aims to outsmart advanced breast cancer